Skip to main
  1. Stocks
  2. Corbus Pharmaceuticals Holdings
  3. Forecast
CRBP

CRBP Stock Forecast & Price Target

CRBP Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Corbus Pharmaceuticals is viewed favorably because its pipeline offers two differentiated shots on goal in large, underpenetrated markets: CRB-701 could address Nectin-4 solid tumors with early signals of improved safety versus Padcev, while CRB-913 showed 5% placebo-adjusted weight loss at 12 weeks with generally mild GI and psychiatric events. The company’s negative EV appears unwarranted given the registrational progress in TEMPO-1 for 2L OPSCC, the prospect of additional 1Q27 data for CRB-701 plus pembrolizumab, and the possibility that even niche adoption in obesity could support meaningful revenue. Although it remains non-revenue-generating with speculative risk and financing uncertainty, its clinical validation milestones and broad commercial optionality make the current valuation look overly discounted relative to the opportunity.

Bears say

Corbus Pharmaceuticals is viewed negatively because its valuation hinges on CRB-701 and CRB-913, both of which face meaningful clinical risk, including the possibility that efficacy proves insufficient or safety signals halt development. As a clinical-stage biotech with no revenues, it also depends on continued financing of ongoing R&D, while setbacks in regulatory approval, manufacturing, or commercialization could further pressure the business. The downside case even assumes shares could trade to $3.00 based on projected cash on hand 1 year from now, underscoring limited margin of safety if trials disappoint.

CRBP has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Corbus Pharmaceuticals Holdings and is not a guaranteed prediction by Public.com or investment advice.

CRBP Analyst Forecast & Price Prediction

Get the latest CRBP stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in CRBP

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Corbus Pharmaceuticals Holdings (CRBP) Forecast

Analysts have given CRBP a Buy based on their latest research and market trends.

According to 7 analysts, CRBP has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Corbus Pharmaceuticals Holdings (CRBP)


CRBP Analyst Forecast & Price Prediction

Get the latest CRBP stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in CRBP

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover CRBP stock data and trends